Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OnKure TherapeuticsOKUR +1.34%14 14-Day RSI is 50.21 as of Aug. 05, 2026. GuruFocus rates OKUR with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,422 Biotechnology companies, OnKure Therapeutics ranks worse than 51.27% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
OnKure Therapeutics 14-Day RSI Related Terms
OKUR vs CRBP, HUMA, ARMP: 14-Day RSI Comparison
For the Biotechnology subindustry, OnKure Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OnKure Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OnKure Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where OnKure Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OnKure Therapeutics (OKUR) has a 14-Day RSI of 50.21 as of Aug. 05, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on OnKure Therapeutics and its competitors. According to the industry distribution chart, OnKure Therapeutics ranks #729 out of 1422 companies in the Biotechnology industry, placing it in the top 51.3%.
Is OnKure Therapeutics' 14-Day RSI too high?
OnKure Therapeutics' current 14-Day RSI is 50.21. The Biotechnology industry median 14-Day RSI is 48.00. OnKure Therapeutics' value of 50.21 is 4.6% above this industry median. Based on the distribution chart, OnKure Therapeutics ranks #729 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OnKure Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does OnKure Therapeutics' 14-Day RSI compare to CRBP and HUMA?
According to the Biotechnology industry distribution chart, OnKure Therapeutics ranks #729 out of 1422 companies for 14-Day RSI. This places OnKure Therapeutics in the lower half of its industry. The industry median 14-Day RSI is 48.00. OnKure Therapeutics' value of 50.21 is 4.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.00, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OnKure Therapeutics's current 14-Day RSI of 50.21 is 4.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on OnKure Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OnKure Therapeutics's current 14-Day RSI is 50.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OnKure Therapeutics stock overvalued right now?
OnKure Therapeutics (OKUR) has a current 14-Day RSI of 50.21. The current 14-Day RSI is 50.21 and 4.6% above the Biotechnology industry median of 48.00. OnKure Therapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For OnKure Therapeutics (OKUR), the current 14-Day RSI is 50.21 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
14GF Score
Get the complete analysis for OKUR
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OKUR has been successfully added to your 
